As children of parents who had cancer we have experienced how devastating the disease can be. We both shifted how we utilize our life for our work to be dedicated to improving the standard of care for patients. DNKO LLC is a collaboration between David Needham PhD, DSc and Katherine Onk. 

Vision
Our overall DNKO vision is that brain cancer patients will have access to a clinically more effective treatment that prioritizes patients before profits and, when tested, may even be curative for the right sized and LITT-heatable tumors.

Mission
Our current DNKO mission is to bring existing and proven technology, specifically Laser Interstitial Thermal Therapy (LITT) and David's invention, the Low Temperature Sensitive Liposomal Doxorubicin (LTSL-Dox) to the brain cancer community, uniting like-minded clinicians to evaluate it, test it and (if it shows promise) bring it as soon as possible to their patients. 

Therapeutics

Life Sciences

DNKO

Org chart

Similar companies